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Abstract: Schizophrenia is a neurodevelopmental disorder featuring chronic, complex
neuropsychiatric features. The etiology and pathogenesis of schizophrenia are not fully understood.
Oxidative-antioxidant imbalance is a potential determinant of schizophrenia. Oxidative, nitrosative,
or sulfuric damage to enzymes of glycolysis and tricarboxylic acid cycle, as well as calcium transport
and ATP biosynthesis might cause impaired bioenergetics function in the brain. This could explain the
initial symptoms, such as the first psychotic episode and mild cognitive impairment. Another concept
of the etiopathogenesis of schizophrenia is associated with impaired glucose metabolism and insulin
resistance with the activation of the mTOR mitochondrial pathway, which may contribute to impaired
neuronal development. Consequently, cognitive processes requiring ATP are compromised and
dysfunctions in synaptic transmission lead to neuronal death, preceding changes in key brain areas.
This review summarizes the role and mutual interactions of oxidative damage and impaired glucose
metabolism as key factors affecting metabolic complications in schizophrenia. These observations
may be a premise for novel potential therapeutic targets that will delay not only the onset of first
symptoms but also the progression of schizophrenia and its complications.
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1. Oxidative Stress, Impaired Glucose Metabolism, Schizophrenia
Schizophrenia is characterized by a significant reduction of both white and gray matter volume
of the brain [1], different levels of anatomical impairment, dysfunction of mitochondrial metabolism,
and specific topological patterns [2–4], especially in the second decade of individual life. This is
confirmed by the computed tomography (CT) and magnetic resonance (MRI) imaging, including the
functional magnetic resonance (fMRI) method [5–7]. Although the trajectory of the indicated changes
remains unexplained, there are reports suggesting their association with early reduction of the volume
of the prefrontal cortex, superior temporal gyrus, and hippocampal gyrus volume reduction [8,9].
The probable mechanism of the observed changes in psychosis may be associated with inflammatory
disorders, dysregulation of the immune system [3,10], neurodevelopmental disorders, including
genetic abnormalities, i.e., 22q11.2 (22q11DS) deletion [11,12], or neutrophil functioning in the severe
forms of mental disorders [10]. Their higher levels strongly correlate with positive clinical symptoms,
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constituting a promising marker of disease progression [13]. In turn, the mentioned genetic disorders
(22q11DS) are the cause of the limited growth of axons and dendrites, which impair the integrity of
mitochondria and functioning of synapses in productive neurons [11]. This is an important factor
linking these changes with trauma, stress, and an increased risk of psychosis among adolescents [12].
The course of schizophrenic disorders can be continuous or episodic, with progressive or
permanent cognitive deficits [14]. The first phase (although different in both genders in terms of
anatomical differences in the white matter of the brain) is similar in most patients and is characterized
by prodromal symptoms: Anxiety, irritability, social withdrawal, and depressed mood [15,16]. Recent
evidence-based data also indicate a strong association between schizophrenia and bipolar disorder
(BD) through a clear relationship between mitochondrial genes in both diseases [17]. Patients may also
experience positive symptoms, i.e., hallucinations and delusions [18]. A late period characterized by
stabilization is a chronic disease with numerous relapses and significant functional disorders [19].
The first psychotic episode (FEP) is the earliest stage of the disease, in which patients exhibit
motivation deficits and impaired decision making related to cognitive impairment. The decreased
desire to put more effort into cognitive functions is caused by the inability to appreciate the reward
or overestimating the amount of effort that should be put into a given activity [20]. Patients with
FEP also have reduced adaptability due to the brain defects in the hippocampus [21]. The difference
between them, and diagnosed schizophrenics, is a shorter history of the disease and/or lack of previous
pharmacotherapy. During the postmortem examination, the brains of people with FEP show evidence
of significant neuropathology involving the enlargement of lateral ventricles, third ventricle, and
brain sulci and fissures. Magnetic resonance imaging (MRI and fMRI) of people with the developing
disease in the prodromal phase shows an enlargement of the right inferior frontal gyrus [8,22], that
directly correlates with reduced neuronal activity in that region. Changes in brain activity are also
observed in regions that include cerebellum, temporal and frontal gyri [23], as well as Heschl’s gyrus,
which is also reduced in people with schizophrenia [24,25]. There are also functional changes in the
region of the insula and amygdala. Those deficits, disturbing neural communication, are clinically
manifested through speech and the disorders of information interpretation, auditory hallucinations,
mood disorders, personality turmoil, and depression [26,27]. A decrease in brain bioelectrical activity
in the inferior left crescent lobe of cerebellum may be associated with negative symptoms [28] in
those patients. In addition, loss of synapses plasticity and impaired electrical conductivity can be
observed, which causes elongation of the nerve impulse path and ultimately the death of neurons [29].
These factors attribute to the clinical phenotype of the disease, in which, apart from mental and
behavioral problems, cognitive disorders occur, including distortions of thinking and perception,
inability to adapt behavior to the situation, or dementia [30], which successively affect executive
functions [31]. Depending on the time of diagnosis, early introduction of appropriate pharmacotherapy
or psychotherapy of patients and their families guarantees complete recovery after the onset of the first
psychotic episode, while its lack becomes the cause of FEP progression into a chronic and full-blown
schizophrenia [32] with a worse treatment prediction [33] and is associated with a reduction in the
chances of patient’s full recovery [34,35].
Pharmacotherapy of schizophrenia faces some problems including polypragmasia resulting from
the lack of standards for the use of polypharmacotherapy [36]. According to the new recommendations
of the American Psychiatric Association of 2020, schizophrenia therapy, especially in younger people
experiencing the first psychotic episode, should be started with atypical drugs, initially at a low dose,
with observation of the response to treatment and side effects [37]. Olanzapine is one of the often chosen
drugs with minor side effects from the extrapyramidal system (in contrast to classical neuroleptics).
Despite initial hopes, it has not become an “ideal” antipsychotic due to the fact that its long-term use is
fraught with a number of cardiometabolic complications, i.e., obesity [38], dyslipidemia, hyperglycemia,
insulin resistance, and diabetes [39]. Its mechanism of action is based, among others, on increasing the
amount of fatty acid binding protein (FABP4) and reducing the amount of apolipoprotein A-IV [40],
which appears to be crucial in the intercellular transport of lipids. This results in a decrease in
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insulin-dependent translocation of membrane glucose transporters (GLUT4) leading to a decrease
in blood glucose uptake [41]. In addition, it is important that the complication of the assessment
of risk related to cardiometabolic syndrome is due to some FEP patients showing impaired glucose
metabolism preceding the use of antipsychotic treatment [42]. This should be taken into account at the
stage of qualifying patients for treatment and during atypical antipsychotics pharmacotherapy based
on recommended dose reduction (“doses must be reduced gradually at a rate of approximately 20%
every 6 months”) [43] as a risk-benefit strategy prior to treatment [37].
One of the key processes that becomes impaired in schizophrenia and its first symptoms is
glucose metabolism. Studies confirm the occurrence of disorders of glucose homeostasis at the early
stages of the disease, such as elevated fasting glucose and insulin, and reduced glucose tolerance [44].
This dysfunction may be associated with neuronal insulin resistance [45]. Glucose is the primary
source of energy for the brain and is metabolized to ATP during glycolysis, the electron transport chain
(ETC), and included in the tricarboxylic acid cycle (TCA) as presented in Figure 1. Glucose enters
the brain from the vascular system through highly efficient GLUT1 and GLUT4 glucose transporters
(Figure 2) [46].
Blocking glucose transporting proteins (GLUT) both centrally and peripherally is the problem of
currently used pharmacotherapy of schizophrenia. An important consequence of this is hyperglycemia
and the development of metabolic syndrome. Out of the well-known antipsychotic drugs, clozapine
blocks GLUT proteins most strongly. Hence, GLUT1 and GLUT3 in the brain are impaired, causing
glucose-malnutrition of neurons. This also prunes neurons, therefore negative symptoms prevail in
patients with schizophrenia, or relapses, associated with positive symptoms and ineffective neuronal
pruning, may occur. Blocking GLUT protein receptors may seem promising and may target the side
effects of antipsychotic drugs while inhibiting neuronal pruning due to disabling already damaged
neurons and their conduction pathways [47].
Glucose transporters such as GLUT1 and GLUT3, are important because they participate in glucose
uptake into both glial cells and neurons. They are not regulated with insulin, but are activated by
systemic hypoglycemia, which stimulates glucose receptors located mainly in hypothalamus (including
GLUT1 and GLUT3) [48]. The situation is different in the case of GLUT1 and GLUT4 transporters,
which are located mainly on the perimeter. In the state of hunger, the GLUT1/GLUT4 ratio increases
and glucose is transported to the brain, whose glucose demand is higher than in the periphery [49].
The brain gets glucose using GLUT1 and GLUT3 transporters, which work so fast that they reduce the
subsequent steps involved in glucose metabolism in the brain. GLUT1 and GLUT3 are immediately
attached to cell membranes. In contrast to these transporters, GLUT4 located in intracellular vesicles
on the periphery through hypoglycemia trigger the hunger mechanism coupled with food acquisition
by stimulating insulin release, so that energy and body mass remain in balance [50]. Transporters such
as GLUT1 and GLUT3 occurring mainly in the frontal lobes are therefore decisive in the brain glucose
metabolism in humans.
Modern theories slightly differ from the classical explanations, and assume that in schizophrenic
patients, absorption of glucose into brain cells is impaired. That can be associated, (among others),
with the wrong concentration of glucose transporters, i.e., GLUT1 and GLUT3, or neuronal insulin
resistance [45]. Our preliminary studies on a group of 40 patients with the first episode of psychosis
(manuscript in preparation) with the use of magnetic resonance spectroscopy (MRS) showed, that the
strongest relationship between the metabolites, i.e., GLU + GLN + GSH 3.7 with positive symptom P
scale was observed in a cingulate cortex. We observed that the higher the value of this ratio, the higher
the p scale score (0.38; p = 0.04, Spearman correlation). This suggests that in the group of patients
with first episode of psychosis, the symptoms of disease get worse, when the brain has insufficient
glucose, in occurrence of intracellular hypoglycemia. That increases with insulin resistance of brain
tissues and inefficient glucose transport, which causes an increase of acute disease symptoms, such as
confusion, misinterpretation of reality, anxiety, and irritability, i.e., characteristics of the prodrome and
the first episode of psychosis [51]. These results, as well as the presented review, indicate the direction
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of further studies on neuronal insulin resistance in young patients with FEP. The observed changes
in insulin signaling associated with impaired glucose metabolism in the brain of patients may be of
clinical significance, as suggested by their strong association with higher P scale results according to
the PANSS clinical evaluation.
Interestingly, in the period of rapid neuronal growth in fetal life and late childhood, intracellular
hypoglycemia causes the transition of symptoms into chronic deficits, which are manifested by a
lack of motivation and a desire to learn, as well as withdrawal of social functions or weakening of
interpersonal communication, which ultimately exacerbates the symptoms and causes the disease to
turn into a chronic form [5,7].
The consequences of this condition affect astrocytes and neurons in the brain, also impairing
the functioning of the glutamine pathway, thereby reducing the availability of glutamate to NMDA
receptors. Results of our imaging studies support the hypotheses mentioned above, because patients
with FEP presented a significantly lower mean value of glutamate GLN 2.45 compared to the control
group (p = 0.001), and compared to a group of patients with multiform behavioral and personality
disorders (p = 0.003). This condition corresponds to the action of NMDA receptor inhibitors, which
intensify the appearance of psychosis, including increased positive and negative symptoms similar to
those observed in schizophrenia.
Insulin resistance is associated with the inability of target tissues to increase glucose uptake in
response to insulin [52]. Insulin resistance of brain tissues can reduce glucose levels in the brain by
glucose-transporter-dependent pathways (among others, GLUT4), which together cause disturbed
neurotransmission and disease progression [53]. Obese patients treated with atypical neuroleptics,
in addition to insulin resistance, develop an additional phenomenon of lipotoxicity, leading to an
increase in the level of free fatty acids (FFA) in the plasma, which is explained by their competition with
glucose as oxidative substrates [54]. It can therefore be concluded that increased fat oxidation causes
insulin resistance in obese people with schizophrenia. Elevated levels of cortisol, an insulin-dependent
hormone associated with inhibition of lipolysis in adipose tissue, are also observed in those patients.
As a result of secondary insulin resistance of target tissues (including adipose tissue), metabolic or
hormonal changes occur, most commonly in visceral obesity through the pathway of multifactorial
inhibition of insulin binding to the GLUT4 receptor located in adipocyte cell membranes [55]. This,
in turn, induces further changes associated with the development of metabolic syndrome and type
2 diabetes observed during treatment of psychiatric patients with second-generation neuroleptics
(e.g., olanzapine, clozapine, risperidone) [56,57]. In the absence of insulin or in case of insulin
resistance of target tissues, as a result of triggering the mTOR pathway, the maturation and the
development of dendritic branches is also impaired together with the proper functioning of neurons.
Mammalian target of rapamycin (mTOR) is an integrated multi-protein serine-threonine kinase
complex, existing in two functional forms of mTORC1 and mTORC2, which can be activated, among
others by growth factors (insulin, insulin-like growth factor IGF-1), stress (DNA damage, decrease
in blood glucose, and oxygen), amino acids such as leucine (Leu) and arginine (Arg), as well as
high ATP levels [58–61]. Activation of each form of the complex is closely related to stimulation of
the PI3K/PTEN/AKT/mTOR tyrosine kinase pathway, which hence linked to synthesis, autophagy,
lipogenesis, ketogenesis, mitochondrial function, glucose uptake, as well as insulin signaling via the
transmembrane receptor tyrosine kinase (RTK) [62,63]. The mTOR pathway controlling neurogenesis,
synaptogenesis, cell proliferation, autophagy, and apoptosis, becomes a very important signaling
pathway, whose disorder leads to serious consequences and is considered an important etiological
factor of schizophrenia. Studies on autophagy-related gene mutations (ATG) in animals are largely
associated with inability to survive [64]. This means that the observed changes in the mTOR pathway
could be the single cause of nerve cell death, which means that their lifetime strictly depends on the
above processes, such as autophagy. The essence of mTOR action is associated with the control of
autophagy, which under physiological conditions prevents the accumulation of misfolded proteins
(e.g., pentosidine) and removes abnormal organelles, including mitochondria, endoplasmic reticulum,
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ribosomes, and even synaptic vesicles (e.g., NR2A), which play a key role in the conduction of nerve
impulses [65]. The mTOR-dependent autophagy disorder seen in schizophrenic patients leads to the
formation of protein aggregates, which consequently promotes toxicity and cell death [66], as well
as to altered synaptic conductivity and mitochondrial dysfunction (e.g., 22q11.2 deletion syndrome).
mTOR may also cause neuronal insulin resistance, glucose deficiency (because insulin and amino
acids directly affecting mTOR are the main regulators of ATG), and consequently reduced glucose
metabolism, abnormal ATP production, as well as dysfunction and/or death of the cells. This pathway
is involved in the translocation of GLUT1 receptors, which are then involved in glucose uptake,
whose lowered levels indicate a disturbance in the mTOR pathway [67]. Adipose tissue taking part in
the regulation of energy metabolism, glucose homeostasis, and insulin sensitivity, becomes insulin
resistant if it contains an impaired mTOR pathway [68,69]. Signal pathways of 3-phosphatidylinositol
kinase, inositol phosphatase (PI3K/PTEN/AKT/mTOR), protein kinase or mitogen activated kinases
(MAPK/ERK) mediated by mTOR can be a mechanism explaining the formation of cardiometabolic
complications of schizophrenia [70]. An animal model showing metabolic syndrome characteristics,
where mTOR pathway inhibitors were administered, was analyzed. As a result, a reduction in
oxidative stress (decrease in superoxide production and NADPH oxidase activity) and inflammatory
response (reduction of macrophage influx), weight loss, reduction of adipose tissue hypertrophy, and
hypertension were observed, which was beneficial to the cardiovascular system and reduced the risk
of cardiometabolic complications [71]. Thus, cerebral insulin resistance in schizophrenia may induce
reduced signal transduction for gamma-aminobutyric acid (GABA), N-methyl-d-aspartic acid (NMDA),
dopamine-D2 receptors, and reduced levels of brain-derived neurotrophic factor (BDNF). KIF3B
protein is involved in the transport of NR2A vesicles to N-methyl-d-aspartate receptors (NMDAR),
which is crucial for neuronal plasticity and synapse formation. KIF3B plays an important role in
the electrophysiological response of NMDAR and hence synaptic plasticity, which is one of the
pathogenetic concepts of schizophrenia [72]. Although the presented studies concern the animal model,
they are of great importance in patients with schizophrenia who were identified with KIF3B mutations.
This confirms the abovementioned research and supports the pathogenic concept of schizophrenia.
Neurexin, a presynaptic protein responsible for the proper joining of neurons into synapses, whose
abnormal expression contributes to the loss of synapses and impaired signal transduction in the brain,
is also directly related to the plasticity of neurons [73]. Together, this contributes to the inflammation
of the local brain tissue, which is driven by local oxidative stress and occurs in the absence of energy
substrates needed by the brain (Figure 3) [74].
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Figure 1. Diagram of glucose metabolism. Blood glucose uptake, glycolysis, citric acid cycle, electron 
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to acetyl-CoA, which is included in the citric acid cycle (TCA), which runs in the mitochondrial 
matrix. There, NADH and FADH2 are produced, which end up in the electron transport chain (I-IV) 
(ETC I-IV), which is located on the inner membrane of the mitochondrion. NADH and FADH2 are 
used to create a proton gradient, which is then used to produce ATP by ATP synthase. Abbreviations: 
1,3-BPG: 1,3-bisphosphoglyceric acid; 2-PG: 2-phosphoglyceric acid; 3-PG: 3-phosphoglyceric acid; α-
KG: Alpha-ketoglutarate; F6P: Fructose-6-phosphate; FBP: Fructose-1,6-bisphosphate; G3P: 
Glyceraldehyde-3-phosphate; G6P: Glucose-6-phosphate; GLUT1: Insulin-independent glucose 
transporter; GLUT4: Insulin-dependent glucose transporter; IR: Insulin receptor; OAA: Oxaloacetic 
acid; PEP: Phosphoenolpyruvic acid. 
One of the etiological concepts of schizophrenia relates to the immune system dysfunction, 
which mainly involves cytokines produced by T lymphocytes [75]. As is known, cytokines circulating 
in peripheral blood can interact with the brain through several mechanisms: Binding to specific 
transporters [76], stimulating the vagus nerve, binding to the receptors in peripheral organs, or 
through a changes in blood-brain barrier permeability with a S100B protein marker of damage [77]. 
Cytokines can also be produced by microglia cells, astrocytes, endothelial cells, and neurons (Figures 
2 and 3) [78]. An abnormal level of circulating cytokines is the cause of inflammation arising from the 
innate immune response and initiated by Toll-like receptors (TLR4) in the course of schizophrenia 
[79]. Changes in TLR4 levels affect the change in neuroplasticity, learning ability, and memory [80–
Figure 1. Diagram of glucose metabolism. Blood glucose uptake, glycolysis, citric acid cycle, electron
Table 1, and an insulin-independent transporter (GL 3). hen, it is metabolize in cytosol in glycolysis
to pyruvic acid, wh h passes into th mit c ondria. Pyruvate dehydrogenase converts it to acetyl-CoA,
which is included in the citric acid cycle (TCA), whi h runs in the mitocho drial atrix. There, NADH
and FADH2 are produced, which end up in the electron transport chain (I-IV) (ETC I-IV), which is located
on the inner membrane of the mitochondrion. NADH and FADH2 are used to create a proton gradient,
which is then used to produce ATP by ATP synthase. Abbreviations: 1,3-BPG: 1,3-bisphosphoglyceric
acid; 2-PG: 2-phosphoglyceric acid; 3-PG: 3-phosphoglyceric acid; α-KG: Alpha-ketoglutarate; F6P:
Fructose-6-phosphate; FBP: Fructose-1,6-bisphosphate; G3P: Glyceraldehyde-3-phosphate; G6P:
Glucose-6-phosphate; GLUT1: Insulin-independent glucose transporter; GLUT4: Insulin-dependent
glucose transporter; IR: Insulin receptor; OAA: Oxaloacetic acid; PEP: Phosphoenolpyruvic acid.
One of t e eti logical concepts of schizophrenia relates to the immune system dysfunction,
which mainly es cytokines produced by T lymphocytes [75]. As is known, cytokines circulating
in peripheral l can interact with the brain through several mechanisms: Binding to specific
transporters [76], stimulating the vagus nerve, binding to the receptors in peripheral organs, or through
a changes in blood-brain barrier permeability with a S100B protein marker of damage [77]. Cytokines
can also be produced by microglia cells, astrocytes, endothelial cells, and neurons (Figures 2 and 3) [78].
An abnormal level of circulating cytokines is the cause of inflammation arising from the innate immune
response and initiated by Toll-like receptors (TLR4) in the course of schizophrenia [79]. Changes
in TLR4 levels affect the change in neuroplasticity, learning ability, and memory [80–82]. Currently
conducted studies on the level of cytokines before and during the development of the disease aim to
outline the therapeutic implications of the distortion of their levels and the usefulness of monitoring
their concentration in schizophrenia [83].
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Another pathogenic concept of schizophrenia emphasizes the role of reduced expression of mGlu2
and mGlu3 metabotropic glutamate receptors found in neuronal membranes. Their activation (by
administering selective mGlu2/3 receptor agonists, e.g., LY379268, clozapine) causes antipsychotic
effects manifested both in the form of reducing psychotic behavior and reversing existing molecular
changes (by reducing the expression of DNMT1 and TET1). The antipsychotic effect is most likely due
to DNA demethylation caused by growth-inhibiting and DNA-damaging Gadd45-β proteins [84,85].
An increase of mitochondrial function, as well as intensified cycles of citric acid and oxidative
phosphorylation, are observed in patients with schizophrenia [86]. Velásquez et al. detected
mitochondrial proteins that differ in their expression from normal levels. CLTC and PPIase A (proteins
associated with endocytosis and protein folding) showed the reduced expression. An elevated level of
eleven proteins associated with the citric acid cycle, electron transport pathway, and participating in
the construction of the mitochondrial membrane has been detected [3], confirming the hypothesis of
mitochondrial dysfunction in the etiopathogenesis of schizophrenia. It was discovered that neurons
are deficient in generating bioenergetics substrates from glucose via the glycolytic pathways, which
could result in TCA cycle abnormalities and impaired OXPHOS [87]. Increased glucose catabolism
confirms the increase in plasma concentration of glycolytic enzymes, lactate, pyruvic acid, insulin, and
GLUT1 [88]. The ratio of lactate and pyruvic acid concentrations is significantly reduced suggesting
the predominance of pyruvate formation [88]. A different level of lactates can be observed in the
cerebrospinal fluid (CSF), where its increase indicates an intensified extra-mitochondrial anaerobic
glucose metabolism [89]. Imaging techniques and metabolomics assessing mitochondrial functions have
allowed the determination of metabolites dependent on oxidative stress or inflammation to identify
pathological changes in the brains of patients with varying degrees of schizophrenia [90–93]. Analysis of
mitochondrial membrane redox potential (via phosphorous magnetic resonance spectroscopy, P-MRS)
of brain tissue and peripheral metabolomics (analysis of blood or fecal metabolites) of patients with
schizophrenia revealed that oxidative modifications of key glycolytic enzymes appear in the affected
areas of the brain (e.g., pyruvate dehydrogenase, fructose bisphosphate, 3-phosphoglyceraldehyde
dehydrogenase, phosphoglycerate kinase-1, phosphoglycerate mutase) [94]. Reduced levels of pyruvate
dehydrogenase results in increased lactate and cellular acidosis and is closely associated with
reduced levels of ATP production in the brain [95], which then leads to reduced glucose metabolism.
Lipid peroxidation observed in schizophrenic patients causes changes in neuronal membranes,
which consequently interferes with their function and affects signal transduction through changes in
neurotransmitters and neuronal receptors located in postsynaptic membranes [96,97]. Oxidative damage
also affects mitochondrial DNA [98], hence it can also contribute to impaired energy production, which
is associated with free oxygen radicals, including superoxide anion radical O2•− and hydrogen peroxide
H2O2 [99]. Thus, both mitochondrial disorders and insulin resistance are closely related, because
the oxidative stress produced in mitochondria interferes with the translocation of insulin-dependent
GLUT4 transporters by accelerating the development of insulin resistance [100].
The metabolic syndrome developed during pharmacotherapy in patients with FEP or schizophrenia
is a key reason for the insulin resistance of brain tissues, which is an important factor of cardiometabolic
risk. Given the very large increase of worldwide metabolic syndrome and type 2 diabetes prevalence
in connection with aging, schizophrenia is a serious and growing problem [101,102]. This review
summarizes the role of oxidative damage and impaired glucose metabolism as key factors affecting
metabolic complications in schizophrenia and highlights the role of a broader approach to schizophrenia
by suggesting new therapeutic options.
The disease occurs long before the first clinical symptoms appear. The prodromal period lasts
from several months to several years. Currently reported problems of the efficacy of schizophrenia
pharmacotherapy may be associated with the late contact with medical personnel. The time between the
onset of FEP and the start of pharmacotherapy varies between 22 and 150 weeks [103]. In addition, the
diagnosis of neuropsychiatric disorders is largely based on subjective cognitive assessment. Due to the
lack of commonly accepted central and peripheral biomarkers for the diagnosis of mental diseases, there
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is a need to search for them according to the newly emerging pathogenetic concepts of schizophrenia
in order to objectify the diagnosis, which will have a direct impact on more effective therapy and less
social burden.
2. Glycation and Oxidative Damage in Schizophrenia
During the reaction of reduction, carbohydrates react with the lysine amino groups of protein
side chains to form advanced glycation end-products (AGEs). The creation of AGEs includes not only
the direct reaction of amino groups of proteins with sugars, but also oxidative damage to proteins as
a result of glycoxidation [104], or the formation of diacarbonyl products of the above reactions, i.e.,
methylglyoxal in the brain [105,106], or pentosidine as a peripheral biomarker of increased carbonyl
stress [107].
Advanced glycation end-products (AGE) are proteins or lipids with sugar residues attached as a
result of exposure to sugars in the glycation process with the participation of RAGE receptors (receptor
for advanced glycation end-products) [108]. RAGE receptors are associated with the cell membrane
of most body cells and can combine with various ligands, including AGE, amphoterin, β-amyloid,
S100/calgranulin [108–112], which results in the activation of proinflammatory pathways that play
an important role in the etiopathogenesis of schizophrenia. esRAGE subtype (endogenous secretory
RAGE) is an unbound form of the RAGE receptor that protects cells from the harmful effects of AGE
in the mechanism of blocking RAGE activation [113]. Reduced levels of esRAGE are observed in
schizophrenic patients, which consequently causes increased exposure to carbonyl stress [114].
Glycoxidation is one of the key reactions of increased carbonyl stress both in the local brain tissue
and in the peripheral blood of schizophrenic patients [114], partly because the reactive compounds of
carbonyl stress form irreversible dysfunctional carbonylated multimer CRMP2 (collapsing response
mediator protein 2) [115], which has a typical AGE structure and binds to RAGE in both neurons and
endothelial cells. The binding of AGE and CRMP2 to RAGE generates further oxidative stress, which
is a direct cause of inhibition of neurite growth, neuronal polarity, and transport of vesicles dependent
on motor proteins, including kinesin superfamily proteins (KIF), regulating structural processes that
affect synaptic transmission, and controlling the dynamics of microtubules in cells and developing
brain [116–118].
Pentosidine classified as AGE has become an important peripheral marker indicating accumulation
of glycation products in the body due to ease its determination [119]. Patients with schizophrenia show
elevated levels of pentosidine with a simultaneous decrease in pyridoxal (active form of vitamin B6),
which is involved in the detoxification of reactive carbonyl compounds (RCCs) and thus counteracts
carbonyl stress [120]. Another compound that counteracts biological stress is betaine, whose levels are
reduced in the course of schizophrenia, resulting in an increase in the concentration of carbonylated
compounds, e.g., Nε- carboxyethyl-lysine (CEL) in the cerebrospinal fluid [121]. In the course of
schizophrenia, reduced levels of glyoxalase 1 (GLO1) are also observed. This enzyme is responsible for
the detoxification of methylglyoxal (MG) by its enzymatic conversion to less harmful compounds, e.g.,
D-lactic acid [122]. Studies in an animal model have shown a reduced GLO1 level in schizophrenia,
resulting in an accumulation of methylglyoxal and thus, modification of behavior, e.g., increased
anxiety and depressive states [123].
Glycation causes a number of undesirable effects in the body. It can slow down the transformation
of proteins, which occurs through conversion into the structure of β-harmonica and fibrils, keeping
them longer in toxic oligomeric forms [124]. Elevated levels of peripheral immune cells, such as
macrophages and monocytes, are observed in schizophrenia [125]. These cells may contribute to the
disturbance of both cholesterol transport from the blood and inflammatory response in the presence of
AGE glycation products, which in turn may cause deformation of blood vessels and atherosclerosis [126].
Vascular disorders associated with protein glycation and the formation of toxic oligomeric forms are
the cause of cognitive decline in schizophrenia [127].
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3. Oxidative, Nitrosative, and Sulfuric Stress in Schizophrenia
Oxidative and nitrosative damage affects macromolecules (i.e., proteins, lipids, or nucleic acids)
during oxidative and nitrosative stress. It occurs when there is an imbalance between the production of
reactive oxygen species (ROS) and reactive nitrogen species (RNS) and antioxidants. Of importance are,
inter alia, endogenous (i.e., superoxide dismutase SOD, catalase, peroxidase, glutathione, thiols, uric
acid, bilirubin) and exogenous antioxidants (i.e., vitamins A (retinol), C (ascorbate) and E (α-tocopherol),
carotenoids, lutein, ubiquitin, glutathione, polyphenols). Oxidative (OxS) or nitrosative (NxS) stress is
very often associated with the pathogenesis of many diseases, including schizophrenia [128–132]. It may
determine the further course of the disease [133] with progression or remission of symptoms [134].
The term ‘reactive’ is variable, which is due to the fact that some ROS and RNS are themselves highly
reactive, e.g., hydroxyl radical (OH•) or nitric oxide (NO), while others become reactive only during
reactions with other radicals, e.g., hydrogen peroxide (H2O2), nitric oxide radical (NO•), superoxide
anion radical (O2•−) (Table 1).
The strongest and most aggressive of the reactive radicals in most biological systems is hydroxyl
radical (OH•), whose standard potential value is equal to +1.902 ± 0.017 V [135]. This radical reacts
with most organic and inorganic compounds including DNA (all purine and pyrimidine bases and
deoxyribose chain), proteins, lipids, amino acids, sugars, and metals [3,7]. The effects of the hydroxyl
radical are associated with increased lipid peroxidation and accumulation of its toxic products in
patients with schizophrenia, which is strongly marked in the blood of patients [136]. That can bring
a better understanding of important biochemical processes locally occurring in the body of these
patients. The effects of lipid peroxidation in patients with schizophrenia also concern vasculitis and
fibrosis [137]. Polyunsaturated fatty acids present in myelin sheaths are particularly sensitive to lipid
peroxidation, becoming a direct cause of demyelination of axons in brain tissue [3].
Another self-reactive radical is superoxide radical O2•−, which acts as a mild oxidant in aqueous
solutions, oxidizing ascorbic acid and thiols. Superoxide radical is a strong reducing agent for iron
found in complexes, e.g., conjugated with cytochrome C or iron from EDTA [3,82]. Irreversible
oxidation of iron-sulfur centers leads to inactivation of the abovementioned complex [7]. As a result of
the reaction of O2•− with highly reactive nitric oxide (NO•), harmful nitrogen forms are formed, e.g.,
peroxynitrites (ONOO−) [3], thanks to which the bioavailability of nitric oxide is reduced, and thus,
the proper blood supply to the vessels is disturbed [1]. This is confirmed by our previous observations
related to the reduced production of peripheral NO2− in patients with the first episode of psychosis,
compared to patients with normotension. The research conducted by Śmierciak et al. confirmed the
relationship between cardiovascular risk associated with inflammation (CRP), lipid profile, and NO2−
production in patients with FEP. This proves that peripheral endothelial dysfunction is associated with
reduced NO2− production. Therefore, modification of endothelial function by increasing NO2− levels
appears as a new therapeutic strategy for patients with FEP [138].
Hydroperoxide HOO•, ozone (O3) [82], and singlet oxygen ( 12 O2) [1,2] are responsible for
peroxidation of lipids, proteins, and nucleic acids, and are more potent oxidant/reducing agents than
superoxide radical. They also have the ability to cross cell membranes into the extracellular space [2]
and to mediate cell signaling [1].
Independently reactive radicals include reactive nitrogen species (RNS) and nitric oxide (II)/(IV)
(NO•), which is a gaseous signal molecule, responsible for vasodilatation and neurotransmission.
Intermediate products formed with the participation of nitric oxide may lead to necrosis of liver cells,
inhibition of mitochondrial function and depletion of pyrimidines, which may result in disruption
of the DNA double helix [3]. Nitric oxide has an effect on ATP production by affecting the electron
transport of the respiratory chain. In the brain, nitric oxide and nitrogen dioxide affect the complexes
I, II, IV, and V of the respiratory chain [78]. The basic biochemical reactions involving nitric oxide
are: S-nitrosylation of thiols, and nitrosylation of transition metal ions [12,79,80]. The structure of
hemoglobin can be changed by direct attachment of NO to the heme in the nitrosylation or S-nirosylation
of thiols, when S-nitrosothiol is formed. Forty five S-nitrosylated proteins were identified in different
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regions of the brain (hippocampus, black matter, cerebral cortex) of Alzheimer’s disease patients, 15 of
which were involved in metabolism (including lactate dehydrogenase) [78]. Glutathione (GSH) can
also undergo S-nitrosylation. In postmortem studies, glutathione reductase levels correlated with
the age of schizophrenic patients. In the absence of antipsychotic treatment, GSH levels may be
reduced [79]. NO and peroxynitrite have a cytotoxic effect on oligodendrocytes [5]. Peroxynitrite
(ONOO−) is another strong oxidant to many biologically active molecules. NO and ONOO− can react
with each other. As a result of this reaction, hydrogen peroxide is formed, which inhibits mitochondrial
respiration, Na+/K+ pump function, and phosphorylation of kinases [3]. Peroxynitrite may cause
nitration (e.g., of protein tyrosine residues) and hydroxylation. In blood vessels, it reacts with carbon
dioxide (CO2). In cells, it oxidizes thiols [81]. The reaction of peroxynitrite with transition metals may
form a hydroxyl radical [3]. Peroxyacid (ONOOH) is a protonated form of peroxynitrite. It is a strong
oxidant produced by activated macrophages, thus showing a positive effect. It may cause oxidation
of thiols, ascorbate, and lipids [81]. Peroxyacid can destroy sulfhydryl groups and cause oxidative
destruction of biomolecules, acting similarly to the hydroxyl radical. It has cytotoxic effects on cells
and mitochondria, causes DNA breaks, protein oxidation, nitration of aromatic amino acids, resulting
in 3-nitrotyrosine [3].
Among radicals that are not reactive independently but reactive with other radicals, both ROS and
RNS are distinguished. Such ROS include, among others, hydrogen peroxide H2O2, which is a weak
oxidant and a weak reducer [82]. As a result of reaction with metal ions (all group D metals except
zinc, e.g., iron and copper), it creates highly reactive radicals including HO• in Fenton reaction [7,83],
whose role in free radical damage to schizophrenic patients was mentioned above. As a result of
the direct action of hydrogen peroxide, the structures of heme proteins are modified with the release
of iron. Hydrogen peroxide also causes inactivation of enzymes and oxidation of DNA, lipids, -SH
groups, and keto acids [3]. Hypochlorous acid (HOCl) has a high oxidative capacity. Its action may
lead to oxidative halogenation of biomolecules such as lipids, proteoglycans, amino acids, as well as
other membrane components and intracellular elements [3]. Organic peroxides (ROOH) are another
group of independently nonreactive ROS. They are formed in the reaction of HO2 with RO2, mainly in
the oxidation of alkanes and alkenes [85]. Organic peroxides are produced by, among others, α- and
β-pyrene, isoprene, limonene, as a result of the decomposition of organic hydroperoxides in the
presence of Fe2+ in the Fenton reaction (OH· is also formed then).
Nitroxyl (HNO) is an example of independently reactive RNS. It can cause direct oxidation of
thiols, which distinguishes it from NO. In the cardiovascular system, it activates cardiac thiol-containing
proteins, e.g., sarcoplasmic ryanodine receptors (RyR2). It causes vasorelaxation by activating soluble
guanyl cyclase (sGC) and further increases in cGMP. It can activate ATP-sensitive and voltage-gated
potassium channels and affect the release of calcitonin gene-related peptide. It causes reduction of
vascular O2•− production. It also has vasoprotective and cardioprotective effects [84]. As a result
of the reaction of NO with NO2, a nitrosyl cation (NO+) [88] and a nitrosyl anion (NO) [81] are
formed. The cation is formed through oxidation, and the anion through reduction. Nitrosyl cation is
responsible for the post-translational modification of thiol-containing proteins, i.e., S-nitrosation of
their thiol groups [88], which can lead to homolysis of S-N bonds. It is accompanied by the release of
NO, formation of S-S bonds, and conformational changes affecting the cell. Nitrosyl cation probably
can also cause the formation of S-nitrosamines. Nitrosyl cation may be present in complexes or
transported, e.g., by S-nitrosoglutathione. NO+ donors have been shown to effectively affect Swiss
3T3 fibroblast and PC12 neuronal cell apoptosis [81]. Some studies suggest that nitrosyl anion may
be formed directly by nitric oxide synthase (NOS). Nitrosyl anion reacts with oxygen resulting in
the formation of peroxynitrite (ONOO−), which occurs during the oxidation of hydroxylamine in an
alkaline environment. Attachment of NO to heme Fe2+ produces NO-nitrosyl heme, from which NO−
can be released. It is believed that nitrosyl anion may be involved in the degradation of S-nitrosothiols
in the presence of thiols. Nitrosyl anion may be responsible for reactions typical of endothelial-derived
relaxing factor (EDRF) and cause double-stranded DNA breaks [81].
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Similar to ROS and RNS, reactive sulfur forms (RSS) perform important biological functions such
as cell signaling, redox homeostasis, and metabolism regulation [106]. RSS are formed as a result of
one-electron oxidation of hydrogen sulfide (H2S). As a result of a number of reactions, sulfhydryl radical
(HS•), thiyl radical (RS•), and persulfide radical anion (‘supersulfide’ (HS2•−) are formed [135,139,140].
Further oxidation of hydrogen sulfide to sulfane sulfur (S0; thiosulfoxide) produces sulfanes (including
hydrogen disulfide H2S2, sulfenic acids RSOH, and elemental sulfur (S)) [139]. Sulfates can then
react with another sulfane sulfur to form polysulfides. Organic RSS can also arise from thiol (RSH)
oxidation [141].
Hydrogen sulfide (H2S) can be synthesized from cysteine, homocysteine, thiosulfates, and carbonyl
sulfide as a result of many different reactions occurring in the cytoplasm and mitochondria [139]. It has
a protective function against OxS and inflammation, as well as a signaling function. The signaling role
of H2S is associated with post-translational oxidative modification of cysteine residues resulting in
cysteine persulfides. H2S may reduce disulfide bonds causing disruption of enzymatic function. It can
be released in an acidic environment (but not under physiological conditions) from the iron-sulfuric
complex belonging to the respiratory chain. SOD oxidizes hydrogen sulfide to polysulphides, which
can then react with subsequent sulphides to form long-chain polysulphides. SOD metabolizes sulfides
to disulfan (H2S2). Polysulphides are also formed, among others, in neurons as a result of the
transfer of sulfuric ion from 3-mercaptenopyruvate to cyanides, other thiols, which catalyzed by
3-mercaptopyruvate sulfurtransferase (MPST), e.g., H2S2 and trisulfan (H2S3) soluble in the brain [142].
In addition to the sources of sulfans and polysulphides mentioned above, they are also generated
in oxidation of hydrogen sulfide by unbound or heme-bound transition metals, myeloperoxidase,
catalase, superoxide dismutase, and other oxidases, as well as the result of H2S metabolism and
cysteine catabolism. Polysulphides can play a protective role against thiols in conditions of oxidative
stress. Disulfanes and polysulfides can be both oxidants and reducing agents, can be used as signaling
molecules or as an energy source. Polysulfides can protect neurons from oxidative stress by activating
Nrf2/Keap1 (nuclear factor erythroid-2-related factor-2/Kelch-like ECH-associated protein 1) pathway.
Polysulfides have been shown to neutralize methyl glyoxal and inhibit its cytotoxicity [142].
Although H2S and polysulphides are necessary for proper functioning, recent studies have shown
that their elevated levels can lead to the development of pathophysiological processes and brain
disorders. MPST expression was elevated in the brains of people with schizophrenia. This suggests
that patients subjected to sulfuric stress have stronger psychotic symptoms. Studies show that elevated
H2S levels in schizophrenic patients already occur at an early stage of the disease development [89].
Blood and plasma tests of schizophrenic and FEP patients showed elevated homocysteine levels, which
probably correlates with the severity of the symptoms. In turn, the level of hydrogen sulfide in the
plasma of patients with schizophrenia was reduced and showed a negative correlation with the severity
of the symptoms. Impaired hydrogen sulfide synthesis may impair the physiological effects of NO,
which may worsen the symptoms of schizophrenia [142].
Intracellular cysteine hydropersulfide (CysSSH) is involved in 2-methylthio-modifications of
t-RNA in mammals, and also affects insulin secretion [7].
Thiyl radicals can also react with OH• causing the formation of very reactive sulfenic acids, which
can, among others, form an intramolecular disulfide bond with cysteine and react with low-molecular
thiols. Sulfenic acids are irreversibly oxidized to sulfinic acid (–SO2H) and sulfonic acid (SO3H) [10,143].
These processes result in an increase in oxidative, nitrosative, and sulfuric damage, which may
include impaired glucose metabolism and the associated loss of ion gradients depending on functional
potential disturbances and Ca2+ transport [144]. During oxidative stress, there is an intracellular increase
in free Ca2+ levels, which are known to have unfavorable consequences, including depolarization of
mitochondrial membranes, oxidative phosphorylation disorders, and overproduction of free radicals.
Moreover, research in schizophrenic patients suggests that changes in mitochondrial function due to
ROS occur before treatment. Hence, the mechanisms of action of psychiatric drugs are both direct and
indirect, suggesting that free radical damage is an etiopathological factor in schizophrenia [91,145].
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As a result of these changes, vital neurons of the frontal cortex, hippocampus, and other regions,
which are physiologically responsible for normal synaptic plasticity and neurotransmitter release are
turned off [24–27]. These neurons affect learning and memory, focus, cognitive functions, and are
responsible for the organization of neurons in the finely-tuned circuits and motor functions during
puberty [27,28].
In addition, DNA oxidative damage, e.g., 8-hydroxydeoxyguanosine, can interfere with gene
transcription and affect promoter function, which can lead to impaired transcription of essential
genes, i.e., suppressor genes, p53 gene, ras gene, and further mutations. In turn, RNA oxidative
damage can damage protein translation, which leads to reduced expression of proteins and loss of
their physiological functions (Table 2) [18,36,37].
Oxidative, nitrosative, or sulfuric damage occurs when specific ROS/RNS/RSS react with
macromolecules, which can be identified by measuring specific reaction products that induce
the abovementioned damage referred to in the literature as ‘oxidative, nitrosative and sulfurative
biomarkers’ [128,146–148]. The most frequently appearing terms for commonly used biomarkers of
oxidative damage to macromolecules, i.e., lipids, proteins, and nucleic acids are summarized in Table 2.
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Table 1. Selected biologically important reactive oxygen species (ROS), reactive nitrogen species (RNS), reactive sulfur forms (RSS).
ROS RNS RSS
Reactive independently
Hydroxyl radical (OH•)
Nitric oxide (II)/(IV) – nitric oxide and
nitrogen dioxide (NO• and NOO)
Sulfhydryl radical (HS•)
Thiyl radical (RS•)
Perhydroxyl radical, the protonated form
of superoxide radical (HOO·) Peroxynitrite (ONOO-)
Persulfide radical anion, ‘supersulfide’
(HS2•−)
Superoxide radical (O2•−)
Protonated form of peroxynitrite
(peroxyacid) (ONOOH)
Sulfenic acids (RSOH), e.g., sulfinic acid
(–SO2H) and sulfonic acid (–SO3H)
Ozone (O3)
Sulfans, np.: Hydrogen disulfide (H2S2),
trisulfan (H2S3)
Singlet oxygen ( 12 O2) Polysulfides (H2Sn)
Not reactive independently,
reactive with other radicals
Hydrogen peroxide (H2O2) Nitroxyl (HNO) Cysteine hydropersulfide (CysSSH)
Hypochlorous acid (HOCl) Nitrosyl cation (NO+) Thiols (RSH)
Organic peroxides (ROOH) Nitrosyl anion (NO−) Hydrogen sulfide (H2S)
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Table 2. Selected peripheral and brain biomarkers of oxidative damage. Biologically important damage to proteins, lipids, and nucleic acids caused by oxidative stress.
ROS Target Directly Measured Product of
Oxidative Damage
Mechanisms Effects
Proteins
3-nitrotyrosine Produced during radical–radical reaction between: Superoxide radical
(O2•−) with nitric oxide (NO•) to form peroxynitrite (ONOO−), which
leads to nitration of Tyr residues in proteins; between the tyrosyl radical
and nitrogen dioxide (•NO2). Moreover, occurs during reactions catalyzed
by peroxidases, including myeloperoxidase (MPO) or eosinophilic
peroxidase. 3-Nitrotyrosine is also formed in a mechanism catalyzed by
modified superoxide dismutase (Cu, Zn-SOD), which has a greater ability
to catalyze the nitration reaction of tyrosine residues caused by ONOO−.
This occurs in motor neurons [149].
Affects the structure and function of proteins in vitro and in vivo;
present in inflammation associated with vascular endothelial
dysfunction and cardiovascular complications in schizophrenia [150].
Correlates with the severity of atherosclerotic lesions; serves as an
independent indicator of the risk of coronary artery disease in patients
with FEP or schizophrenia. Biomarker, whose level depends on the
pharmacotherapy, e.g., clozapine induces oxidative and nitrosative
stress (in the caspase-3, NF-κB p65 or Nrf2 mechanism) depending on
the dose in the cardiovascular system [151–153].
Protein carbonyls Carbonylated proteins are formed in the course of the following
mechanisms:
1. The formation of aldehydes due to the cleavage of the peptide chain
resulting in the formation of free radicals that convert into aldehydes;
2. Formation of oxidized amino acid side chains (oxo-histidine);
3. Combining proteins with lipid peroxidation products;
4. Creating advanced glycation end-products (AGEs).
Protein carbonyls increase: Carbonyl stress; production of
conformationally altered polypeptide chains, which contributes to
cellular dysfunction; excessive aggregation of proteins by promoting
unfolding and formation of noncovalent, as well as covalent bonds
between proteins; increased toxicity; may lead to apoptotic cell death
[154,155].
Dityrosine Can be formed as a result of metal-catalyzed bond formation between two
tyrosine residues. The reaction proceeds to form a tyrosine radical that
isomerizes the entire aromatic ring. As a result of the combination of two
radicals in the ortho–ortho position, an unsaturated bis-ketone is formed,
which leads to the formation of dityrosine [156]. The change is irreversible
[157].
Affects the redox state disorder; elevates the level of inflammatory
factors, causing oxidative damage to the hippocampus; contributes to
the deterioration of learning and memory skills [158].
It may contribute to the amino acid metabolism disorder and inhibit
energy production [159].
Methionine sulfoxide Hydrogen peroxide reacts with methionine residues at pH = 5 to form
methionine sulfoxide. Under these conditions, cysteine residues are
resistant to methylation. Cysteine thiol group must first be ionized in
order to be oxidized. At acidic pH, methionine is oxidized by dimethyl
sulfoxide to methionine sulfoxide. At neutral or alkaline pH it is oxidized
under the influence of hypochlorous acid, oxygen, ozone, peroxynitrite,
superoxide radical [160]. Under the influence of further oxidation,
methionine sulfoxide can be converted to methionine sulfone [157].
Methionine sulfoxide reductase is present in many organs, including
the brain. It has a protective function against the effects of oxidative
stress. Disturbances in the functioning of methionine sulfoxide
reductase may have a significant impact on the development of many
diseases, including schizophrenia. Various genetic variations of
methionine sulfoxide reductase have been demonstrated in
schizophrenic patients. They may be associated with dopamine
disorders and affect the effects of treatment. These genetic variations
affect various traits related to brain function. Chronic stress is
associated with overexpression of methionine sulfoxide reductase in
the hippocampus [161].
S-carboxymethyl-cysteine
S-2-succinyl-cysteine
Under the influence of glyoxal or glucose on cysteine residues, protective
amino acids, peptides containing thiol groups, and proteins form
S-carboxymethyl-cysteine, which has been recognized as AGE. Studies
show that thiohemiacetal that was initially formed undergoes an
intramolecular Cannizzarro reaction [162]. S-succinyl-cysteine is formed
as a result of a nonenzymatic Michael reaction under the influence of
fumaric acid on the free thiol groups of cysteine residues [157,163].
Fumarate, leading to the formation of S-(2-succinyl-cysteine, causes
irreversible inhibition of many sulfhydryl enzymes. One of them is
3-phosphoglyceroldehyde dehydrogenase, which belongs to the
glycolytic pathway, which is impaired in the course of schizophrenia
[164].
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Table 2. Cont.
ROS Target Directly Measured Product of
Oxidative Damage
Mechanisms Effects
Carboxymethyllysine Formed as a result of various reaction mechanisms, i.e., oxidation of
fructosyl-lysine (reaction chain leading to AGE), direct reaction of glyoxal
with the ε-amino group of lysine (reaction chain leading to ALE) [162,165],
oxidation of lysine, proline residues, arginine and threonine [130].
Important AGE-epitope and RAGE ligand. It causes systemic
glycoxidant load and increased body’s susceptibility to stress [165].
Cysteine/cystine
Homocysteine/homocystine
Homocysteine and cysteine are reduced forms, homocystine and cystine
are oxidized forms [166]. Homocysteine is a product of metabolism
(demethylation) of methionine. It is sensitive to autoxidation and can be
converted into cysteine [167].
The accumulation of homocysteine and the lack of further metabolism
of this compound causes a disorder of thymidine synthesis, DNA
replication and neurogenesis, as well as the synthesis of
neurotransmitters leading to a disorder of brain conductance [168].
Cysteine, which is a precursor of antioxidative glutathione, exhibits
elevated levels in schizophrenia, compensating for the increase in
oxidative stress [169].
Lipids
Lipid peroxides Formed during oxidation of polyunsaturated long-chain fatty acids, e.g.,
linoleic, arachidonic, and docosahexaenoic acids. Hydrogen from the
methyl group is removed first, resulting in the formation of two double
bonds. Then, the fat is isomerized, a diene is formed, which reacts with
molecular oxygen, leading to the formation of lipid peroxide. The second
mechanism is based on oxidation catalyzed by metals (iron, copper). As a
result of the Fenton reaction, radicals are formed that remove hydrogen
from the methyl group, further reaction proceeds as described above [170].
Inhibits glycolysis and synthesis of proteins and nucleic acids. Leads
to the disorders in the transport of glucose and glutathione, damaging
cholinergic neurons and accelerating apoptosis of neurons. Binds to
thiol groups of proteins or to glutathione, reducing their level in the
cell; binds to amino groups of proteins or DNA nitrogen bases,
initiating mutagenesis and carcinogenesis processes. The
concentration in schizophrenic patients is higher in both the brain and
the periphery [171,172].
They probably inhibit Na, K-ATPase activity by lipid peroxidation,
which leads to disruption of the phospholipid moiety [173].
Malondialdehyde MDA is formed during conversion of methyl linoleate to
prostaglandin-like endoperoxide, which is considered a precursor of MDA
under stress. Another mechanism is the production of hydrogen peroxide
and β-cleavage of the fatty acid chain. Hydroperoxyaldehyde is then
formed, from which MDA is generated as a result of β-scission or due to
the reaction of the acrolein radical with a hydroxyl radical. MDA can also
be formed during the enzymatic biosynthesis of thromboxane A2
[130,134,174].
Inhibits glycolysis and synthesis of proteins and nucleic acids. Leads
to the disorders in the transport of glucose and glutathione, damaging
cholinergic neurons and accelerating apoptosis of neurons. Binds to
thiol groups of proteins or to glutathione, reducing their level in the
cell; binds to amino groups of proteins or DNA nitrogen bases,
initiating mutagenesis and carcinogenesis processes. The
concentration in schizophrenic patients is higher in both the brain and
the periphery [171,172].
4-hydroxynonenal Oxidation of polyunsaturated fatty acids, i.e., linoleic, linolenic,
arachidonic, and docosahexaenoic acids, by lipid peroxides [175].
Generally formed from omega-6 acids via β-fragmentation of
15-hydroperoxyarachidonic acid and 13-hydroperoxylolenic acid [130,134].
HNE induces the formation of protein adducts, which then become the
cause of a toxic neuronal disorder. Increases permeability of BBB and
endothelium of blood vessels [175,176].
F2-isoprostanes Eicosanoids result from the peroxidation of long-chain polyunsaturated
fatty acids (mainly omega-3 and omega-6), e.g., arachidonic acid by OH•
[130,134,177].
Highly reactive products formed by the metabolism of isoprostanes
(isoketals and their protein adducts). Inhibits the activity of
simpleasomes, contributing to neurodegeneration [178,179].
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Table 2. Cont.
ROS Target Directly Measured Product of
Oxidative Damage
Mechanisms Effects
DNA
8-hydroxydeoxyguanosine Formed during oxidation (hydroxylation of the C-8 position) of nucleotide
guanine by OH•.
Leads to the destruction of DNA, which causes an increase in
mutagenicity, cancer risk, and neurodegenerative diseases [177,180].
Uracil, xanthine, oxanine Exposure of DNA to RNS (N2O3—product of NO. auto-oxidation) causes
deamination of bases and conversion of cytosine to uracil
(2’-deoxyuridine), guanine to xanthine (2’-deoxyxanthosine), oxanine
(2’-deoxyoxanine) (in the presence of HNO2 at acidic pH), and
8-nitroguanine [181,182].
The correct level of uracil incision, abasic site cleavage, and dNTP
incorporation activities in mitochondria originating from brains of
patients with AD was examined [183]. Reduced activity of xanthine
oxidase in the thalamus and occipital cortex of patients with chronic
schizophrenia was observed. Studies show that elevated levels of
xanthine oxidase also occur in the blood of schizophrenic patients
[184].
8-nitroguanine .NO2 and NOO− react with guanine contained in DNA bases, nucleosides,
and nucleotides, resulting in the formation of 8-nitroguanine [185,186].
The presence of 8-nitroguanine has been shown in hepatocytes,
Kuppfer’s cells, and inflammatory cells of patients with chronic
hepatitis C [187]. 8-Nitroguanine can lead to the formation of tumors
and is detected in cancer cells [188,189].
5-chlorocytosine Formed under the direct influence of HClO on cytosine contained in DNA
[190].
5-Chlorocytosine may serve as a biomarker for chronic inflammation.
The presence of 5-chlorothyrosine predisposes to mutagenesis [191].
5-chlorouracil Formed due to the enzymatic deamination of 5-chlorocytosine [190]. Exhibits genotoxic and antimitotic effects [192].
5-hydroxymethyluracil
5-hydroxyuracil
Formed under the influence of ROO• [191]. Oxidation of cytosine to
unstable cytosine glycol which undergoes deamination leads to the
formation of 5-hydroxyuracil [193]. 5-hydroxymethyluracil can be formed
in two mechanisms:
• Oxidation of thymine and a formation of the base with adenine;
• Formation under the influence of ROS, for example H2O2 with
5-methylcytosine. Then, 5-hydroxymethylcytosine is formed, which
undergoes deamination to 5-hydroxymethyluracil, forming a base
pair with cytosine [194].
Elevated levels of 5-hydroxyuracil have been observed in vulnerable
regions of the brains of patients in the late stages of Alzheimer’s
disease [195]. Elevated levels of 5-hydroxyuracil have also been
observed in other brain regions (such as temporal, parietal, and frontal
lobes) with AD. Elevated levels of 5-hydroxyuracil in mtDNA were
examined in the parietal and temporal lobes of AD brains, while
neocortex showed an increased content of 5-hydroxyuracil in nuclear
DNA [196]. A reduced level of incision and 5-hydroxyuracil ligase
activity in mitochondria from brain postmortem investigations was
demonstrated in patients with AD [183]. 5-Hydroxymethyluracil plays
an important role in DNA demethylation. It can serve as a cancer
biomarker [197].
Etheno-DNA-adducts Reactive compounds formed in ROS-induced modification reactions, e.g.,
modified lipids, react with DNA either directly or through bi-functional
intermediates, creating mutagenic etheno-DNA adducts, e.g., γ-linolenic
acid peroxidation products as 4-hydroxynenenal react with adenine,
cytosine, and guanine. This results in the formation of
1,N6-etheno-2’-deoxyadenosine (εdA), 3,N4-etheno-2’-deoxycytidine
(εdC), 1,N2-etheno-2’-deoxyguanosine (1,N2εdG), and
N2,3-etheno-2’-deoxyguanosine (N2,3εdG) [198].
Can be used as cancer markers [199]. They are carcinogenic and play
an important role in initiating the process of hepatocarcinogenesis
[200]. They are detected in the livers of patients with nonalcoholic
steatohepatitis (NASH) [201] and alcoholic liver disease (ALD) [200].
RNA 8-hydroxyguanosine Hydroxylation of nucleotide guanine by OH•, H2O2, O2•− [202]. Increased serum 8-hydroxyguanosine levels have been demonstrated
in patients with traumatic brain injury, which correlated with mortality
[201]. Its occurrence is associated with many chronic diseases in old
age, including Alzheimer’s disease [200], dementia and Parkinson’s
disease [201].
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Oxidative, nitrosative, sulfur (SxS) stress, and inflammation disturb brain development [203].
The stress can affect neuronal plasticity, signal transduction, and induce apoptosis [129,204]. It is
believed that OxS markers and inflammation may be important indicators of the course of schizophrenia
and provide information on the disease progression and the effectiveness of treatment [128]. The brain
of schizophrenic patients contains increased levels of oxidative/nitrosative/sulfuric damage products,
i.e., 4-hydroxy-2-nonenal (HNE), 3-nitrotyrosine or homocysteine, associated with the trans-sulfur
pathway [143]. Interestingly, the increase in HNE was associated with the accumulation of iron
in the black matter, a region of the brain heavily affected by pathology [175], while an increase in
3-nitrotyrosine levels was seen in the prefrontal cortex of patients with psychosis [205]. In the case
of antioxidative system indicators, there was a decrease in the activity of key antioxidative enzymes,
i.e., glutathione peroxidase (GPx) or superoxide dismutase (SOD). The aforementioned intensification
of lipid peroxidation expressed by increased levels of malondialdehyde (MDA) was identified in the
blood of people with psychosis [206], although these changes did not correlate with executive functions
(EF) in patients with chronic schizophrenia [206].
In relation to carbonyl stress in the course of schizophrenia, hyper-carbonylation of a collapsin
response mediator protein (CRMP2) [115] was observed in the brain and cerebrospinal fluid of patients.
Increased levels of carbonylated proteins in the cerebrospinal fluid of the studied patients support the
theory of carbonyl stress [157]. Interestingly, increased levels of AGEs, which are also significantly
associated with carbonyl stress in schizophrenia, were characteristic of people with treatment-resistant
disease [207]. In contrast, esRAGE, which is one of the soluble forms of RAGE, is considered to be a
key carbonyl stress suppressant by binding to AGEs. As indicated, lower levels of both esRAGE and
sRAGE in the serum can be associated with the functional haplotype of people with schizophrenia in
whom AGEs are the main cause of carbonyl stress [114].
The consequences of OxS/NxS/SxS in the brain may include disorders of glucose metabolism
and thus disturb the ion gradient with impaired conductivity in the area of action potential and Ca2+
imbalance [157]. Oxidative stress increases intracellular levels of free Ca2+ which can lead to impaired
energy supply. Energy in the form of ATP necessary for the proper functioning of neurons originating
from oxidative phosphorylation from the inner mitochondrial membrane can be regulated, inter alia,
by intracellular Ca2+ level [207,208]. Ca2+ stored in the endoplasmic reticulum (ER) is quickly and
effectively transported to the mitochondria through mitochondria-associated ER membranes (MAM).
MAM has a DISC1 (disrupted-in-schizophrenia 1) on its surface—a scaffold protein that is credited with
affecting the function of intracellular organelles, i.e., mitochondria, centrosomes, endosomes, lysosomes,
and affecting receptor degradation, as well as regulating intracellular transport [209] associated with
cognitive and personality disorders [210]. DISC1 reacts with the type 1 inositol 1,4,5-triphosphate
receptor (IP3R1) and inhibits its binding to the inositol triphosphate (IP3) ligand, affecting Ca2+
transfer through MAM between ER and mitochondria. DISC1 mutations cause oxidative/carbonyl
stress during which hydrogen peroxide, superoxide anion, and C2-ceramide impair the transport of
Ca2+ in mitochondria, leading to its penetration from ER through IP3Rs. The presented mechanism
becomes the cause of depolarization of mitochondrial membranes, oxidative phosphorylation disorders,
and overproduction of free radicals, resulting in the exclusion of vital neurons of the frontal cortex,
hippocampus, etc., which are physiologically responsible for the normal synaptic plasticity and
the release of neurotransmitters [211–214]. Thus, they affect learning and memory, focus, cognitive
functions, and are responsible for the organization of neurons in the finely-tuned circuits and motor
functions during puberty [214,215].
Studies show that there are other mechanisms of Ca2+ transport that affect mitochondrial function.
Thus, mitochondrial ryanodine type 1 receptor (mRyR1) found in cardiac cells and neurons is better
suited for Ca2+ transport between endoplasmic reticulum and mitochondrion and plays the key role
in mitochondrial uptake of Ca2+ [216]. Increased levels of Ca2+ in the cytoplasm causes Ca2+ to
accumulate in the mitochondrial matrix and consume the mitochondrial membrane potential that affects
the mitochondrial ability to produce ATP [217] and regulate dehydrogenase activity in the citric acid
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(Krebs) cycle (glycerophosphate dehydrogenase, pyruvate dehydrogenase, isocitrate dehydrogenase,
α-ketoglutarate dehydrogenase) [216,217]. Reversible phosphorylation of the Ca2+-mediated pyruvate
dehydrogenase complex partially regulates the supply of reducing equivalents. Activation of the
Krebs cycle increases the production of nicotinamide adenine dinucleotide (NADH), which causes the
electrons of the complex I of the respiratory chain to move to complex IV [217]. Activation of these
reaction chains leads to increased ATP synthesis [216]. These disorders are associated with working
memory deficits and changes in the short-term hippocampus strengthening [218] and impairment of
motor skills [219].
The respiratory chain I complex and the cytochrome c oxidase subunit are regulated by specific
protein kinases and phosphatases [220,221]. Cyclic-adenosine-3′,5’-monophosphate-dependent kinase
catalyzes the phosphorylation of the complex I subunits. When the Ca2+ level is low, phosphatases
dephosphorylate and inactivate the complex I [217], whereas when the Ca2+ level is high, mitochondrial
phosphatase dephosphorylates cytochrome c oxidase and inactivates its allosteric inhibition [222].
Uncoupling proteins catalyze the controlled leakage of protons from the mitochondria through
the inner membrane. They may be associated with the regulation of Ca2+ uniport, which affects Ca2+
homeostasis and, hence, the ATP level. Uncoupling proteins 2, 4, and 5 are present in the central
nervous system and are thought to protect neurons from excess Ca2+ and OxS. Uncoupling protein 4
regulates Ca2+ homeostasis and affects Ca2+ influx into the endoplasmic reticulum [217].
In addition, DNA oxidative damage by, e.g., 8-hydroxydeoxyguanosine, can interfere with gene
transcription and affect promoter function, which can lead to impaired transcription of essential genes,
i.e., suppressor p53 ras genes, and further mutations. In turn, RNA oxidative damage can impair
protein translation, which leads to reduced expression of proteins and loss of their physiological
functions (Table 2) [157,223,224].
Traditional OxS identification methods focus on molecular biomarkers that are determined by
chemical analytical methods [128,225–236].
The antioxidant defense system is designed to protect against the harmful effects of free radicals.
In the literature, one can find many studies devoted to particular antioxidants, whose activity or
concentrations correlate with the course of free radical reactions [232,236]. Cooperation between
different antioxidants results in a greater protective effect than would result from the sum of the
antioxidant effects of each compound separately [130]. There are various terms in the literature
regarding total antioxidant capacity (TAC), which examples are presented in Table 3.
Table 3. Total antioxidant capacity with regards to the key reactions for their determination.
Oxidative Potential Found in
Literature Key Reaction References
TAC (total antioxidant capacity) AN = NA→ [A·N2·A]
−N2
−−−→ 2A·
A·+ O2 → AO2·
R−PE
−−−−→ stable product
AO2·+ AO2· → stable product
R-PE: R-phycoerythrin
[233,237–239]
TAP/TAOP (total antioxidant
power/potential)
Assessed via FRAP method:
FeIIITPTZ + antioxidant→ FeII-TPTZ
[230,240,241]
TRAP (total radical-trapping
antioxidant parameter)
RN = NR 37
◦C
−−−→ [R·N2·R]
−N2
−−−→ 2R·
2O2
−−−→ 2ROO·
RN = NR (ABAP)
[232,236,242]
TRAP (total reactive antioxidant
potential)
Assessed via the method proposed by Lissi et al.
LH2
−H
−−→ LH·
O2
−−→ LO2H· LHOOH
↘ ↙
hν
ROO·+ LH2 → ROOH + LH·
[232,243]
TAR (total antioxidant reactivity) Assessed using the abovementioned method [228]
Biomolecules 2020, 10, 384 19 of 38
Table 3. Cont.
Oxidative Potential Found in
Literature Key Reaction References
TAR (total antioxidant response) Based on the method proposed by Miller et al.
ABTS - 2,2′-azinobis-(3-ethylbenzothiazoline)-6-sulphonic acid
ABTS
peroxidase (e.g. metmyoglobin),H2O2
−−−−−−−−−−−−−−−−−−−−−−−−−−−→ ABTS·+
[228,240]
TAA (total antioxidant activity) Fe− EDTA + H2O2 → OH·
bsodium benzoate
−−−−−−−−−−−−→ TBARS antioxidants−−−−−−−−→
TBARS suppression
[240,244]
TAS (total antioxidant status) ABTS - 2,2′-azinobis-(3-ethylbenzothiazoline)-6-sulphonic acid
ABTS
peroxidase (e.g. metmyoglobin),H2O2
−−−−−−−−−−−−−−−−−−−−−−−−−−−→ ABTS·+
[228,245,246]
TPAC (total plasma antioxidant
capacity/capability)
AN = NA→ [A·N2·A]
−N2
−−−→ 2A·
A·+ O2 → AO2·
R−PE
−−−−→ stable product
AO2·+ AO2· → stable product
R-PE: R-phycoerythrin
[237,238,247]
NEAC (nonenzymatic antioxidant
capacity)
AN = NA→ [A·N2·A]
−N2
→ 2A·
A·+ O2 → AO2·
R−PE
→ stable product
AO2·+ AO2· → stable product
R-PE: R-phycoerythrin
[134,238]
Ir-reducing capacity
(iridium-reducing capacity)
Ir(IV) + e− → Ir(III)
IrOX + e− → IrRED
K2IrCl6(IV) + e− → Ir(III)
[128,248]
The estimation of the total antioxidant capacity as a clinical exponent of OxS is associated with a
different approach consisting in the determination of:
• Concentrations of single or all low molecular weight antioxidants in plasma, serum, saliva, and
other biological materials [92,134];
• Activity of selected enzymes [92,249];
• OxS markers, e.g., 8-hydroxyguanosine or MDA as exponents of lipid peroxidation [92,249,250].
Total antioxidant capacity of plasma is the result of the action of low molecular weight
antioxidants (e.g., α-tocopherol, ascorbic acid, β-carotene, glutathione, uric acid, bilirubin), proteins
(e.g., ceruloplasmin, ferritin, albumin, transferrin), and enzyme systems [130–132]. OxS-induced
decrease in TAC is eliminated by the increase of antioxidant enzyme activity and activation of
nonenzymatic mechanisms. In the latter phase of OxS, a decrease in TAC is observed, which is caused
by the exhaustion of antioxidant defense mechanisms [251].
The clinical significance of antioxidative potential determination is associated with the assessment
of the increased risk of certain diseases and their complications (including schizophrenia) or the
impact of treatment on compensatory elements associated with the antioxidant defense of the
organism [92,129,240,252]. Another approach proposes to use a single general OxS marker, which
is a moderately strong oxidant K2IrCl6(VI)—IrOX, to obtain chemical data on OxS. This approach
does not focus on the determination of a specific chemical compound, but detection of environmental
characteristics that indicate disturbances between oxidative and reducing activity [128].
Interestingly, serum OxS determinations correlate with the occurrence and course of schizophrenia,
which suggests that OxS in CSN occurs earlier which may be identified already in the early stages of the
ongoing pathology. In addition, OxS data correlate with indicators of damaged BBB in schizophrenic
patients, which combines the concept of oxidative stress and neuritis [128] with the pathogenesis
of schizophrenia [253,254]. Morphological changes in the structure of capillaries and cells of the
neurovascular unit (NVU) occur in the prefrontal and visual cortex of schizophrenic patients, along
with vacuole destruction of endothelial cells, astrocyte-foot processes, and the reduction of baseline
membrane thickness [254] (Figures 2 and 3). Changes in tight junctions are observed in the brains
of schizophrenic patients [253,255], which are reflected in the reduction of expression of 12 out of 21
genes associated with their formation compared to the control group [254]. It has been shown that
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tight junctions can be broken [253], which has been associated with the presence of large areas lacking
claudin-5, whose expression is reduced in the prefrontal cortex of patients with schizophrenia [253–255].
Claudin-5 proteins are absent along the blood vessels of the brain of schizophrenic patients, which
may be associated with the penetration of low-molecular blood elements, e.g., S100β, resulting
in impaired brain homeostasis [253]. The calcium-binding S100β protein is mainly produced by
astrocytes [253,256,257]. An increase in plasma S100β levels shows a positive correlation with the
occurrence of negative symptoms of schizophrenia and cognitive disorders [254].
The relationship between neuroinflammation, oxidative stress, endothelial damage, and impaired
mitochondrial metabolism due to the dysfunction of the blood-brain barrier in patients with
schizophrenia is presented in Figure 3. Vascular disorders associated with hyper-permeability of
the blood-brain barrier can impair many functions simultaneously: They can affect cognitive and
behavioral functions associated with neuroinflammation in the microglial area, which leads to a
deepening process of neurodegeneration in the CNS [258]. According to the conception of de la
Monte [259], neurodegeneration may be called type III diabetes or CNS metabolic disease, where it
comes to an increase in oxygen, nitrogen, and sulfuric free radicals (ROS, RNS, RSS) [260] due to
activation of inflammatory pathways (and increased release of proinflammatory cytokines, e.g., IL-6,
IL-1B, TNF-α, by glial cells and astrocytes) [261]. It causes mitochondrial damage and activation of
a number of kinase pathways, e.g., MAP, JNK, and p38MAPK, which may also result in inhibition
of insulin signaling [262]. Disorders of glucose metabolism in the CNS increase the production of
ketone bodies and the activation of additional pathways mediated by free radicals, including NF-kB [7].
According to the literature data, insulin axis impairment and hypometabolism in the CNS cause loss of
neurons, astrocytosis, and microgliosis mainly within amygdala and septum [263], axonal damage and
demyelination of the hippocampus and fornix [264]. McNay et al. indicate that insulin signaling and
abnormal glucose transport significantly affect cognitive processes and memory functions regulated
by the hippocampus [265]. This is due to the incorrect activation of the insulin-sensitive GLUT4
transporter on the periphery and GLUT1–3 in the brain tissue [10]. Abnormal glucose metabolism can
also affect the integrity of white and gray matter due to the effect of hyperglycemia on the dynamics and
function of mitochondria, which leads to the accumulation of ROS and impaired axonal transport [266],
mainly within the thalamus, parietal lobe, and hippocampus [267].
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regulated by protein complexes located between endothelial cells, i.e., ESAM, AQP4, GLUT1, 
PECAM, JAMs, VE-cadherin, peripheral proteins of tight junctions (ZO1÷3), claudine (3, 5, 12), and 
occludin. GLUT3 is seen in neurons, and GLUT1 in endothelial cells; GLUT2 is a glucose sensor 
present in the hypothalamus in the brain. In the course of schizophrenia, the GLUT1 translocation 
process, and thus glucose transport, is impaired, among others due to the effect of harmful oxidative 
stress, inappropriate mitochondrial metabolism, and impaired mTOR pathway. BBB also regulates 
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patients can be broken due to the presence of claudin-5-deficient areas. Their expression is reduced 
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Figure 2. Structure of the neurovascular unit (NVU) with particular attention to the glucose metabolism
impairment. (A) NVU contains the blood-brain barrier (BBB) which consists of many different cells
including astrocytes, pericytes, neurons, microglia, and endothelial cells. The brain cells can work with
each other when metabolic demand on glucose and other substrates is eno gh. BBB provides crossing
of important ubstrates for mitochondrial metabolism, e.g., glucose, removal of toxic super xides, e.g.,
carbon d oxide, an reduce access to the brai of potentially damaging m lecul s in the bloodstream,
e.g., some drugs. BBB constitutes a protection against harmful factors due to the echanisms of
active intercellular transport or control by proteins transporting energy substrates located in the
vascular endothelial cell membrane (e.g., GLUT1). (B) Intracellular transport is regulated by protein
complexes located between endothelial cells, i.e., ESAM, AQP4, GLUT1, PECAM, JAMs, VE-cadherin,
peripheral proteins of tight junctions (ZO1÷3), claudine (3, 5, 12), and occludin. GLUT3 is seen in
neurons, and GLUT1 in endothelial cells; GLUT2 is a glucose sensor present in the hypothalamus in
the brain. In the course of schizophrenia, the GLUT1 translocation process, and thus glucose transport,
is impaired, among oth rs due to the eff ct f harmful oxidative stress, inappropriate mitochondrial
metabolism, and impaired mTOR pa hway. BBB also regulates t excha ge of other components, e.g.,
calcium, elements of the immune system, or indicators of neurobiochemical focal lesions, i.e., S100β
protein. Tight connections in the brains of schizophrenic patients can be broken due to the presence of
claudin-5-deficient areas. Their expression is reduced in the prefrontal cortex and they are absent along
the blood vessels, which may be associated with the penetration of S100β through BBB and, consequently,
with a disorder of brain homeostasis. Abbreviations: AQP4: Aquaporin 4; BBB: Blood-brain barrier;
ESAM: Endothelial cell-selective adhesion molecule; GLUT1: Insulin-independent glucose transporter;
JAM: Junctional adhesion molecule; NVU: Neurovascular unit; PECAM: Platelet-endothelial cell
adhesion molecule; VE-cadherin: Vascular endothelial cadherin; ZO1÷3: (B) Peripheral proteins of
tight junctions (zonula occludens).
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the transsulfuration pathway (low activity of cystathionine β-synthase and cystathionine γ-lyase) 
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Figure 3. Impact of oxidative stress on blood-brain barrier (BBB) permeability. Excessive ROS, produced
among others by mitochondria, may lead to oxidative stress, which may disrupt mitochondrial functions,
as well as induce an increase in the level of proinflammatory cytokines. This consequently leads to an
increase in the level of VCAM-1 and BBB permeability. Proinflammatory cytokines (for ed after the
activation of micr glial cells) and ROS ca also directly affect BBB permeability. The redu ed H4/BH2
ratio activates the eNOS uncoupling cycle, which increases L-argini e levels. Its increas d level, as
well as participation of NAD(P)H oxidase, BH4, O2, and eNOS leads to the formation of L-citrulline,
NO, and superoxide radical (O2•−). NO reacts with O2•−, resulting in highly reactive, harmful
peroxynitrite (ONOO−) forms, whereas the NO levels decrease. NO is responsible for vasodilatation of
vessels. A decrease in its level causes a reduction in vasodilatation and, as a consequence, cerebral
hyperperfusion. Cerebral hyperperfusion may be the result of reduced astrocyte-foot process and AQP4
levels. Their reduction ca also directly lead to oxidative stress. The formation of angiotensin-I from
angiotensin-II is catalyzed by ACE, which contributes t cerebral hyperperfusion, as well. Elevated
ACE levels may promote the production of proinflammatory cytokines. Bradykinin can be both
produced due to reactive oxygen species and lead to their formation. It exhibits a cytotoxic effect
on endothelial cells and leads to inflammation of the nervous tissue. Stimulation of VEGF is also
associated with an increased BBB permeability. Abbreviations: ACE: Angiotensin-converting enzyme;
AQP4: Aquaporin 4; BBB: Blood-brain barrier; BH4/BH2: Tetrahydrobiopterin/dihydrobiopterin; eNOS:
Nitric oxide synthase; MMP: Matrix metalloproteinase; NO: Nitric oxide; NAD(P)H: Nicotinamide
adenine dinucleotide; O2•−: Superoxide radical; ONOO−: Peroxynitrite; ROS: Reactive oxygen species;
VCAM-1: Vascular adhesion molecule; VEGF: Vascular endothelial growth factor.
Progression of schizophrenia is increasingly associated with the treatment-resistant (TRS) form
of the disease. The severity of symptoms is the result of sulfuric stress and is positively correlated
with high levels of homocysteine and the failure of transsulfuration process, which metabolizes
homocysteine in the l-cysteine pathway [143,268]. l-cysteine deficiency and lack of response from
the transsulfuration pathway (low activity of cystathionine β-synth se and cystat ionine γ-lyase)
become the cau e of the recorded low levels of glutathione and glutathione pathway enzymes (i.e.,
GPx) in the brain and blood of patients with schizophrenia [269]. As a consequence, the level of
hydrogen sulfide (H2S) decreases and the oxidative phosphorylation (OXPHOS) pathway containing a
number of proteins that have iron and sulfur in their structure is impaired. During sulfuric stress, the
synthesis of these iron and sulfur-containing proteins is deregulated, which directly strikes OXPHOS,
which becomes inefficient in schizophrenia. Consequently, the molybdenum cofactor (MoCo), which
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requires sulfur (from L-cysteine), affects the dependent sulfite oxidase (SUOX), which detoxifies sulfites
from sulfur-containing amino acids. If the SUOX is low, sulphite toxicity, which is a component
of oxidative-nitrosative-sulfuric stress, may occur, which may result in a decrease in the synthesis
of selenoproteins, i.e., GPx, observed in schizophrenia and its first symptoms [270]. Sulfuric stress
increases damage to macromolecules, i.e., DNA or proteins (in the carbonylation process), leading to
methylation of genes and histones, affecting epigenetic changes in TRS.
Although H2S and polysulfides are necessary for proper functioning, recent studies have shown
that their elevated levels can lead to the development of pathophysiological processes and brain
disorders. MPST expression was elevated in the brains of people with schizophrenia. This suggests
that patients with this disease subjected to sulfuric stress have stronger psychotic symptoms. Studies
show that increased levels of H2S in schizophrenic patients occur at an early stage of the disease
development [89].
The presented pathogenetic mechanisms related to oxidative, nitrosative, or sulfuric stress,
impaired glucose metabolism, and mitochondrial dysfunction may constitute a therapeutic target for
existing antipsychotic drugs and alternative therapies for TRS. It could be directed at the disorders of
oxidative-antioxidative regulation, mitochondrial metabolism, as well as regulation of other pathways,
resulting from glucose metabolism dysregulation.
4. Conclusions
Observations in this manuscript, as well as our own research (papers are being prepared), is
strengthening the theory of impaired glucose metabolism at an early stage of schizophrenia. Our paper
attempts to bring the recipients closer to a multidisciplinary approach to schizophrenia, as a disease
involving the complexity of the brain pathology process, in correlation with peripheral changes.
This article aims to draw attention of the public, mainly physicians dealing with the younger
generation, to expand the panel of diagnostic tests to facilitate the assessment of impaired glucose
metabolism as a factor determining the state of the brain and the progression of mental illness over
time. Research in this area can be helpful in reduction of stigma associated with the disease, and can
be useful in the process of monitoring the treatment of affected individuals.
The presented manuscript points out scientific evidence to the role of oxidative, nitrosative, sulfuric
antioxidative damage, which is a key element of pathomechanism and progression of schizophrenia
and its symptoms. Glucose metabolism, which is the main source of energy for the brain, is impaired
in schizophrenia and the first symptoms of psychosis. These changes are largely due to impaired
oxidation of key glycolytic proteins or energy production in the form of ATP. Smaller energy supplies
to the ‘necessitous’ brain cause a number of changes including the exclusion of vital functions, such
as impaired functional potential or increased levels of intracellular Ca2+, altering the basic functions
of neurons.
Reactive forms of oxygen, nitrogen, or sulfur are the cause of oxidative, nitrosative, and sulfuric
damage inducing lipid peroxidation, protein carbonylation, or glycation. This creates reactive molecules
that critically affect the proteins of the mitochondrial metabolism in the brain, changing its functions
and promoting the symptoms of schizophrenia.
Presynaptic membranes are particularly sensitive to oxidative stress, leading to impairment of
cognitive functions and motivation, and ultimately to impairment of perception of reality. Affected
neurons die, leading to the clinical manifestation of schizophrenia. As a neuropathology, it may be
preceded by a prodrome or may be resistant to treatment, hence understanding the pathomechanism of
the disease and increased efforts to better understand the biochemical, genetic background, or imaging
techniques assessing anatomical or functional changes in the brain, seems necessary.
Given the increasing percentage of people with diabetes or cardiovascular disease in the group of
people with schizophrenia along with an aging population, impaired glucose metabolism or insulin
resistance seem to be more common in the general population. They require targeted therapies aimed
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at impaired glucose metabolism and reducing oxidative, nitrosative, and sulfuric stress, and thus
protecting the brain from threatening neuropathological changes disabling its basic functioning.
In this work, an attempt was made to present the main pathogenic pathways of schizophrenia
caused by an oxidative-antioxidant imbalance that impairs glucose metabolism, leading to the weakened
neural conduction and neuronal death.
Considering the role of individual brain cells, i.e., glial cells associated with bioenergetics of
brain processes, glucose metabolism dysfunctions, and accelerated aging of neurons in schizophrenia,
current research should focus on the mechanisms highlighted in this paper. That can significantly
contribute to understanding the consequences of this disease already at the stage of its early symptoms.
This in turn can lead to the development of effective therapeutic strategies for those struggling with
this severe disease.
In our further research, we will present the results of events regarding the sequence of changes
described in this manuscript, which should also be taken into account trying to determine the
pathomechanism of the disease and understand the development of treatment-resistant forms, as well
as a strategy for more effective therapy directed at oxidative stress, impaired glucose metabolism, and
neuronal death.
Available imaging techniques in combination with effective biomarkers of disease progression
stand open to new possibilities of testing schizophrenic patients and open potential new ways of
treatment, which hopefully will arise for a new generation of patients suffering from schizophrenia.
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36. Ordak, M.; Nasierowski, T.; Muszyńska, E. The pharmacological basis of drug interactions: An aspect
overlooked in psychiatry. Lancet Psychiatry 2019, 6, 984. [CrossRef]
37. Shimomura, Y.; Kikuchi, Y.; Suzuki, T.; Uchida, H.; Mimura, M.; Takeuchi, H. Antipsychotic treatment in
the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms.
Schizophr. Res. 2019. [CrossRef]
38. Correll, C.U.; Lencz, T.; Malhotra, A.K. Antipsychotic drugs and obesity. Trends Mol. Med. 2011, 17, 97–107.
[CrossRef]
39. Correll, C.U.; Robinson, D.G.; Schooler, N.R.; Brunette, M.F.; Mueser, K.T.; Rosenheck, R.A.; Marcy, P.;
Addington, J.; Estroff, S.E.; Robinson, J.; et al. Cardiometabolic risk in patients with first-episode schizophrenia
spectrum disorders baseline results from the RAISE-ETP study. JAMA Psychiatry 2014, 71, 1350–1363.
[CrossRef]
40. Yang, N.; Yu, L.; Deng, Y.; Han, Q.; Wang, J.; Yu, L.; Zhai, Z.; Li, W. Identification and characterization of
proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by
iTRAQ quantitative proteomics. J. Proteom. 2019, 212, 103570. [CrossRef]
41. Xu, P.T.; Song, Z.; Zhang, W.C.; Jiao, B.; Yu, Z.B. Impaired translocation of GLUT4 results in insulin resistance
of atrophic soleus muscle. BioMed Res. Int. 2015, 2015, 291987. [CrossRef]
42. Greenhalgh, A.M.; Gonzalez-Blanco, L.; Garcia-Rizo, C.; Fernandez-Egea, E.; Miller, B.; Arroyo, M.B.;
Kirkpatrick, B. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve
patients with nonaffective psychosis. Schizophr. Res. 2017, 179, 57–63. [CrossRef] [PubMed]
43. Grover, S.; Chakrabarti, S.; Kulhara, P.; Avasthi, A. Clinical practice guidelines for management of
schizophrenia. Indian J. Psychiatr. 2017, 59, 19. [CrossRef]
44. Pillinger, T.; Beck, K.; Gobjila, C.; Donocik, J.G.; Jauhar, S.; Howes, O.D. Impaired glucose homeostasis in
first-episode schizophrenia. JAMA Psychiatry 2017, 74, 261–269. [CrossRef] [PubMed]
Biomolecules 2020, 10, 384 27 of 38
45. Kapogiannis, D.; Dobrowolny, H.; Tran, J.; Mustapic, M.; Frodl, T.; Meyer-Lotz, G.; Schiltz, K.; Schanze, D.;
Rietschel, M.; Bernstein, H.G.; et al. Insulin-signaling abnormalities in drug-naïve first-episode schizophrenia:
Transduction protein analyses in extracellular vesicles of putative neuronal origin. Eur. Psychiatry 2019, 62,
124–129. [CrossRef]
46. Jurcovicova, J. Glucose transport in brain—Effect of inflammation. Endocr. Regul. 2014, 48, 35–48. [CrossRef]
[PubMed]
47. De Silva, P.N. Does the association with diabetes say more about schizophrenia and its treatment?—The
GLUT hypothesis. Med. Hypotheses 2011, 77, 529–531. [CrossRef] [PubMed]
48. Agarwal, S.M.; Caravaggio, F.; Costa-Dookhan, K.A.; Castellani, L.; Kowalchuk, C.; Asgariroozbehani, R.;
Graff-Guerrero, A.; Hahn, M. Brain insulin action in schizophrenia: Something borrowed and something
new. Neuropharmacology 2020, 163, 107633. [CrossRef] [PubMed]
49. Zhang, X.; Yang, M.; Du, X.; Liao, W.; Chen, D.; Fan, F.; Xiu, M.; Jia, Q.; Ning, Y.; Huang, X.; et al. Glucose
disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia.
Mol. Psychiatry 2019. [CrossRef]
50. Fernandez-Egea, E.; Walker, R.; Ziauddeen, H.; Cardinal, R.N.; Bullmore, E.T. Birth weight, family history of
diabetes and diabetes onset in schizophrenia. BMJ Open Diabetes Res. Care 2020, 8, e001036. [CrossRef]
51. Laurens, K.R.; Luo, L.; Matheson, S.L.; Carr, V.J.; Raudino, A.; Harris, F.; Green, M.J. Common or distinct
pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk
factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry
2015, 15, 205. [CrossRef] [PubMed]
52. Sesti, G. Pathophysiology of insulin resistance. Best Pract. Res. Clin. Endocrinol. Metab. 2006, 20, 665–679.
[CrossRef] [PubMed]
53. Wijtenburg, S.A.; Kapogiannis, D.; Korenic, S.A.; Mullins, R.J.; Tran, J.; Gaston, F.E.; Chen, S.; Mustapic, M.;
Hong, L.E.; Rowland, L.M. Brain insulin resistance and altered brain glucose are related to memory
impairments in schizophrenia. Schizophr. Res. 2019, 208, 324–330. [CrossRef] [PubMed]
54. Carpentier, A.C.; Bourbonnais, A.; Frisch, F.; Giacca, A.; Lewis, G.F. Plasma nonesterified fatty acid intolerance
and hyperglycemia are associated with intravenous lipid-induced impairment of insulin sensitivity and
disposition index. J. Clin. Endocrinol. Metab. 2010, 95, 1256–1264. [CrossRef] [PubMed]
55. Norris, D.M.; Geddes, T.A.; James, D.E.; Fazakerley, D.J.; Burchfield, J.G. Glucose transport: Methods for
interrogating GLUT4 trafficking in adipocytes. Methods Mol. Biol. 2018, 1713, 193–215. [CrossRef] [PubMed]
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Rogóż, Z.; Lorenc-Koci, E. Glutathione deficiency and alterations in the sulfur amino acid homeostasis
during early postnatal development as potential triggering factors for schizophrenia-like behavior in adult
rats. Molecules 2019, 24, 4253. [CrossRef]
270. Mullier, E.; Roine, T.; Griffa, A.; Xin, L.; Baumann, P.S.; Klauser, P.; Cleusix, M.; Jenni, R.; Alemàn-Gómez, Y.;
Gruetter, R.; et al. N-acetyl-cysteine supplementation improves functional connectivity within the cingulate
cortex in early psychosis: A pilot study. Int. J. Neuropsychopharmacol. 2019, 22, 478–487. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
